Meta Pixel

News and Announcements

Free VS Paid: How To Establish Product Market Fit

  • Published December 14, 2022 7:13AM UTC
  • Publisher Osama Hassan
  • Categories Capital Raising Tips

When establishing product market fit, and building initial traction, a lot of founders don’t charge users. 

It’s based on the assumption that for a product that should be paid, if you make it free, you can get honest feedback in-exchange. 

I think this is a flawed approach. 

It’s okay to be free in certain cases where you have a structured and intentional plan in place to getting paid. 

We know that freemium, open-core, and ad-supported business models work. 

All you have to do is read up on how Slack, Dropbox, GitLab and WordPress started.

Sometimes, you just have to get a lot of free users before you can start making a lot of money. 

But these are exceptions to a well-established norm. 

Why? Because investors are looking for returns and will not invest in your startup if your business has no potential to generate recurring, sustainable revenue. 

The trick to getting paid users is to make sure that you’re not charging out of fear or are worried about not getting a second chance to put new pricing out there. 

Remember, if you’re not charging, you’re preventing yourself from learning if your product is something people REALLY want. 

✌️

Click here to view the original Linkedin post.

Looking for a platform to raise capital? Click here to discover how Wholesale Investor can help you.

Your capital engagement platform

With a 14-year track record, a network of 32,000+ investors, and a capital raising platform, Wholesale investor is a leading investment platform for start-ups, scale-ups, emerging growth companies, and small caps.

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now